Kessler Harald H
Institut für Hygiene, Karl-Franzens Universität Graz.
Wien Med Wochenschr. 2003;153(15-16):336-41. doi: 10.1007/s10354-003-0005-4.
Tuberculosis is one of the leading infectious diseases in the world. Using conventional methods, the isolation, identification, and drug susceptibility testing of Mycobacterium tuberculosis and other clinically important mycobacteria can take several weeks. During the past several years, molecular methods have been developed for direct detection, species identification, and drug susceptibility testing of mycobacteria. These methods can potentially reduce the diagnostic time from weeks to hours. For direct detection of Mycobacterium tuberculosis from clinical specimens, several molecular assays are commercially available today. They have been shown useful for the routine diagnostic laboratory. DNA probes and polymerase chain reaction-based sequencing have been widely used to identify mycobacterial species. Molecular methods have also been applied for the detection of mutations that confer drug resistance in mycobacteria. All in all, the future of clinical mycobacteriology appears to be heading toward direct detection, species identification and drug resistance determination using molecular methods.
结核病是世界上主要的传染病之一。使用传统方法,结核分枝杆菌和其他临床上重要的分枝杆菌的分离、鉴定及药敏试验可能需要数周时间。在过去几年中,已开发出用于分枝杆菌直接检测、菌种鉴定及药敏试验的分子方法。这些方法有可能将诊断时间从数周缩短至数小时。如今有几种分子检测方法可用于从临床标本中直接检测结核分枝杆菌。它们已被证明对常规诊断实验室很有用。DNA探针和基于聚合酶链反应的测序已被广泛用于鉴定分枝杆菌菌种。分子方法也已应用于检测分枝杆菌中赋予耐药性的突变。总而言之,临床分枝杆菌学的未来似乎正朝着使用分子方法进行直接检测、菌种鉴定和耐药性测定的方向发展。